Policy Briefings

Research

Policy Briefs
Publications
Research Projects

Policy Briefs
Publications
Research Projects

14th Release 2025

In recent years, declining birth rates, the increasing variety of vaccines, and the growing demand for adult immunizations have led to a decrease in childhood National Immunization Program (NIP) vaccination volumes at primary healthcare facilities, while demand for adult immunizations has been on the rise.

13th Release 2024

Rotavirus gastroenteritis (RVGE) is a global public health problem that seriously threatens the health of children under 5 years old, causing up to 200,000 mortality of children each year. In China, the burden of RVGE remains substantial and is difficult to prevent and control.

12th Release 2024

Compared to young and middle-aged adults, older adults bear a higher disease burden and lower immunity against viruses. Some epidemics are more likely to outbreak in places where the elderly gather, such as nursing homes.

11th Release 2024

Currently, most of China’s regions handle procuring and distributing its National Immunization Program (NIP) and non-NIP vaccines separately. Different entities or stakeholders undertake the distribution of NIP and non-NIP vaccines from the vaccine manufacturers to the county and district-level CDCs.

10th Release 2024

The susceptibility to infections during pregnancy underscores the importance of vaccinations for disease prevention. Maternal immunization has been proven to safeguard pregnant women, their fetuses, and infants from various infections, and international practices confirm the safety and efficacy of several vaccines for pregnant women.

9th Release 2024

The number of vaccine doses required for children in China far exceeds the international level. Promoting the use of combination vaccines for children is an important measure to significantly reduce the number of doses and increase children's immunization coverage, bringing multiple benefits.

8th Release 2023

The age-standardized incidence and mortality rates of cervical cancer in China are rapidly growing and it increasingly affects younger individuals, underscoring the critical need for the accelerated uptake of the HPV vaccine.

7th Release 2023

6th Release 2023

Compared to the National Immunization Program (NIP) vaccines, which have nearly universal coverage in China, the uptake of non-NIP vaccines among children under the age of 6 remains low and exhibits significant geographic and population variations.

5th Release 2023

Non-national immunization program (non-NIP) vaccines play an important role in the prevention and control of key infectious diseases. However, there are still issues with high prices and low vaccination rates for non-NIP vaccines in China.

4th Release 2023

Streptococcus pneumoniae is a commonly carried bacterium in the nasopharynx of Chinese children and can lead to serious health conditions such as pneumonia, meningitis, and lifelong sequelae. The diseases caused by this bacterium not only harm children, but also place a significant economic burden on families.

3rd Release 2022

Implementing immunization programs is the most cost-effective way to control infectious diseases. China’s national immunization program (NIP) has achieved remarkable progress over the past decades, though there is still room for optimization to achieve effective development in the future.

2nd Release2022

Cervical cancer is the fourth most common cancer in women and the second leading cause of death among women with cancer in China between 15 and 44 years of age.

1st Release 2022

Non-national immunization program (non-NIP) vaccines are vaccines outside China’s national immunization program (NIP) system that citizens voluntarily vaccinate at their own expense.